Molecular Tumor Board at the Center for Personalized Medicine TÃ¼bingen
Molecular Tumor Board at the Center for Personalized Medicine
Advanced Cancer
OTHER: no intervention
Progression-free survival, Progression-free survival, 6 months
Overall survival, Progression-free survival, an average of 1 year
Molecular Tumor Board at the Center for Personalized Medicine The study objectives are

* To ensure a prospective documentation of all patients who are referred to the Molecular Tumor Board in routine clinical care
* To prospectively ensure the documentation of MTB patients with an emphasis to clinical outcome parameters progression-free survival (PFS), overall survival (OS) and further response assessments (e.g. peripheral immunmonitoring, imaging parameters)
* To prospectively assess patient-reported outcome of MTB patients
* To evaluate compliance to MTB suggestions in routine clinical care